Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Indications for transmyocardial laser therapy]

B Maisch1, R Funck, U Schönian

  • 1Zentrum für Innere Medizin-Schwerpunkt Kardiologie, Marburg.

Zeitschrift Fur Kardiologie
|January 1, 1996
PubMed
Summary

Transmyocardial laser therapy (TMR) offers symptomatic relief for end-stage coronary artery disease (CAD) patients unresponsive to conventional treatments. While not improving prognosis, TMR can alleviate angina and dyspnea in over 60% of cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[2019 ESC guidelines: consensus in Europe for 25 years].

Herz·2019
Same author

[The 4 R of the ESC guidelines 2018: relevance, redundancy, reality, and relativization].

Herz·2018
Same author

[Management of pericarditis and pericardial effusion, constrictive and effusive-constrictive pericarditis].

Herz·2018
Same author

Heart failure 2.0 or 0.1?

Herz·2018
Same author

Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulins.

Herz·2018
Same author

[ESC guidelines 2017 : What is new and what is of particular importance?]

Herz·2017

Area of Science:

  • Cardiology
  • Minimally Invasive Procedures
  • Regenerative Medicine

Context:

  • End-stage coronary artery disease (CAD) presents limited treatment options after maximal medical therapy and revascularization attempts.
  • Diffuse arteriosclerotic vessel morphology often precludes further interventional or surgical interventions.
  • Transmyocardial laser therapy (TMR) is considered a palliative option for symptom management in these refractory cases.

Purpose:

  • To evaluate the efficacy and safety of Transmyocardial Laser Therapy (TMR) as a treatment for symptomatic end-stage coronary artery disease (CAD).
  • To assess TMR's impact on angina class, dyspnea, myocardial perfusion, and overall survival.
  • To explore potential pathophysiological mechanisms underlying TMR's therapeutic effects.

Summary:

  • A registry of 101 end-stage CAD patients treated with TMR showed symptomatic improvement (angina/dyspnea) in over 60% of cases.
  • Scintigraphy indicated improved myocardial perfusion in some patients, though central hemodynamics and ejection fraction remained largely unchanged.
  • Six-month mortality was 11% for TMR patients, marginally lower than historical controls on medication alone (14%), but higher than patients eligible for PTCA/CABG.

Impact:

  • TMR provides a valuable palliative option for patients with end-stage CAD, significantly improving quality of life by reducing symptoms.
  • Further research is needed to elucidate the long-term patency of TMR-created channels and their precise contribution to myocardial perfusion.
  • Understanding TMR's mechanisms may lead to refined therapeutic strategies for ischemic heart disease.

Related Experiment Videos